Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Hallek, Michael, Coiffier, Bertrand, O'Brien, Susan, Tausch, Eugen, Kreuzer, Karl-Anton, Jiang, Wendy, Lazarov, Mirella, Li, Daniel, Jahn, Thomas M. and Stilgenbauer, Stephan (2014). Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG (R)) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sharman, Jeff Porter, Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Hallek, Michael J., Coiffier, Bertrand, O'Brien, Susan Mary, Tausch, Eugen, Kreuzer, Karl A., Jiang, Wendy, Jahn, Thomas Michael, Lazarov, Mirella and Stilgenbauer, Stephan (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Fri May 7 02:50:20 2021 CEST.